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Background: A wide range of human in vitro methods have been developed and there
is considerable interest in the potential of these studies to address questions related to
clinical (human) use of drugs, and the pathobiology of tumours. This requires agreement
on how to assess the strength of evidence available (i.e., quality and quantity) and the
human-relevance of such studies. The SAToRI-BTR (Systematic Approach To Review of
in vitro methods in Brain Tumour Research) project seeks to identify relevant appraisal
criteria to aid planning and/or evaluation of brain tumour studies using in vitro methods.
Objectives: To identify criteria for evaluation of quality and human relevance of in vitro
brain tumour studies; to assess the general acceptability of such criteria to senior
scientists working within the field.
Methods: Stage one involved identification of potential criteria for evaluation of in vitro
studies through: (1) an international survey of brain tumour researchers; (2) interviews
with scientists, clinicians, regulators, and journal editors; (3) analysis of relevant reports,
documents, and published studies. Through content analysis of findings, an initial list of
criteria for quality appraisal of in vitro studies of brain tumours was developed. Stage
two involved review of the criteria by an expert panel (Delphi process).
Results: Results of stage one indicated that methods for and quality of review of
in vitro studies are highly variable, and that improved reporting standards are needed.
129 preliminary criteria were identified; duplicate and highly context-specific items were
removed, resulting in 48 criteria for review by the expert (Delphi) panel. 37 criteria
reached agreement, resulting in a provisional checklist for appraisal of in vitro studies
in brain tumour research.
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Conclusion: Through a systematic process of collating assessment criteria and
subjecting these to expert review, SAToRI-BTR has resulted in preliminary guidance
for appraisal of in vitro brain tumour studies. Further development of this guidance,
including investigating strategies for adaptation and dissemination across different
sub-fields of brain tumour research, as well as the wider in vitro field, is planned.
Keywords: in vitro, quality appraisal, evaluation, critical appraisal, brain tumour, cancer, systematic review
INTRODUCTION
There is currently a drive to review the use of animals in
research for both scientific and ethical reasons. A wide range of
in vitro methods have been developed and, increasingly, there are
suggestions that these can replace the use of animals in research
(NC3Rs, 2020). In order for in vitro studies to be considered
for replacement of in vivo (animal) studies to answer questions
related to the clinical (human) use of drugs and pathobiology of
tumours, there must be agreement on the strength of evidence
available (i.e., the quality and quantity of studies) as well as
their relevance. Judging the strength of evidence requires that
all relevant research is located, each research study is assessed
for quality and, if appropriate, the results of the individual
research studies are combined to give an overall ‘answer’
and/or a clear picture of the current research on the topic in
question. This process can also reveal poor research practises,
unreliable reporting of research and unnecessary replication and
duplication (Hartung et al., 2019). Any such practises, if left
undetected, would render efforts to replace animal research less
likely to gain acceptance.
Methods for assessing clinical (human) studies are well-
developed, led by organisations such as the international
Cochrane collaboration (Higgins and Green, 2011). ‘Systematic
reviews’ of the evidence are regularly published (over 140,000
systematic reviews are listed on PubMed as of March 2020). Well-
conducted systematic reviews of clinical studies are widely used as
the basis for clinical decisions.
A parallel development has taken place for animal studies.
CAMARADES (Collaborative Approach to Meta-Analysis and
Review of Animal Data from Experimental Studies) is an
initiative to improve the design, conduct, analysis and reporting
of animal experiments (CAMARADES, 2020). By means
of ‘precise and robust’ overviews of existing data through
systematic review and meta-analysis, CAMARADES aims to
clearly demonstrate where further experiments are necessary,
avoiding unnecessary replication. The CAMARADES initiative
has generated interest and collaborative efforts on a global scale
with five national coordinating centres. This is seen as crucial in
efforts to reduce animal experimentation.
Reduction strategies, however, constitute only one of the
Three Rs (Refinement, Reduction, and Replacement) – the
underlying principles of ethical and humane use of animals in
research (NC3Rs, 2020). The third principle, replacement, as
described above, requires that a desired scientific goal is achieved
by approaches other than those involving live animals, such
as through use of in vitro studies. As with the CAMARADES
initiative ‘precise and robust’ overviews of existing research are
essential to provide a clear picture of the research (Nuffield
Council on BioEthics, 2005). However, as Hartung et al. observe,
‘[while] [m]any areas have developed reporting standards and
checklists to support the adequate reporting of scientific efforts. . .
in vitro research still has no generally accepted criteria. . . [and]
such a culture may undermine trust in the reproducibility of
animal-free methods’ (Hartung et al., 2019). Thus, there is a need
to evaluate and develop current practises for assessing quantity
and quality of in vitro studies of brain tumours and their potential
to replace in vivo (animal) studies.
As Hartung et al. (2019) indicate, issues in reporting are not
restricted to specific areas of interest (such as brain tumours)
but encompass the broad field of in vitro research. Searches on
a major scientific database (PubMed) reveal that while reviews
have been published and described as systematic reviews of
in vitro studies, many fail to apply key principles and processes
expected of such studies. For example, one publication reported
the databases searched and inclusion criteria, but not whether any
quality criteria were applied (Laaksonen et al., 2010). A second
‘systematic review’ assessed each study based on two criteria
defined by the authors (type of publication and whether there
was a ‘comparable baseline’), and reported the lack of generally
accepted evaluation criteria for in vitro studies (Xiao et al., 2011).
A third review revised an existing tool for assessing diagnostic
studies using four selected criteria (Deng et al., 2016). Few details
are reported on exactly how these criteria were applied. Another
study attempted to provide an overview of guidance systems with
evaluation criteria for in vitro studies on chemical toxicity (Lynch
et al., 2016). The criteria compared were from four sources
[Animal Research: Reporting of in vivo Experiments (ARRIVE)
(Kilkenny et al., 2010), Klimisch et al. (1997) on evaluating the
quality of toxicological data; OECD Guidance Document on the
Validation and International Acceptance of New or Updated Test
Methods for Hazard Assessment (OECD, 2005); Toxicological
Data Reliability Assessment Tool (ToxRTool) (Schneider et al.,
2009)]. The criteria include reporting requirements, categories to
be scored and items to be assessed. Few criteria were common
to all 4 sources. Furthermore, while criteria for assessment of the
quality of studies is crucial for unbiased, reliable reviews of the
research literature, assessment of relevance of the technique or
method employed is also a key element.
Both development of reporting standards for in vitro research
(Hartung et al., 2019) as well as adoption of existing guidance
(Pamies et al., 2017; Hartung et al., 2019) remain issues across the
broad field of in vitro research. This study specifically focuses on
brain tumour research, with the intention of providing a model
for other areas. We have selected brain tumour as a particular
area for study because although many brain tumours can be
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cultured in the laboratory with relative ease, there are specific
challenges in gaining accurate biological information from cells
which have been removed from such a complex multicellular
organ as the brain. Not only are brain tumour cells reliant on
the non-neoplastic cells such as glial and immune cells for their
resistance to therapeutics, but they are also reliant on the very
special vasculature of the brain and indeed the blood brain barrier
which protects against toxins but inhibits delivery of therapeutics.
Provision of sophisticated, complex 3D models of the brain
and its vasculature, including organoids, induced pluripotent
stem cells and blood brain barrier elements for pre-clinical drug
delivery and sensitivity are perhaps the most complex forms of
all human tissue in vitro systems and, if we can produce best
practise criteria for this area we can roll this out for many other
areas of research.
The overall aim of the SAToRI-BTR project is to explore how
in vitro studies could be presented as a body of knowledge in
the form of a rigorous and comprehensive systematic review,
to assess the potential for replacement of animal studies for
answering specific questions in brain tumour research. SAToRI-
BTR seeks to address these challenges by assessing reviews of
existing studies (published systematic reviews) and identifying
areas for potential improvement and investigating current
practise and views on how in vitro studies of brain tumours
should be assessed, leading to agreed criteria.
The aim of the study reported in this paper was to
explore potential methods for the systematic identification, and
assessment of quality and appropriate use of in vitro studies
through a process involving identification of existing criteria
which were subject to expert review in order to develop
draft criteria.
MATERIALS AND METHODS
The project to develop a set of appropriate criteria for assessment
of quality and human relevance in in vitro studies of brain
tumours was carried out in two stages. The first stage involved
identification for potentially relevant criteria through collection
and analysis of appropriate data (stage one), and the second
stage focused on obtaining agreement on identified criteria by
an expert panel by means of a Delphi process (stage two –
see Figure 1).
The overall process followed that developed by the EQUATOR
(Enhancing the QUAlity and Transparency Of health Research)
Network which was used for development and agreement on
reporting guidelines for systematic reviews (PRISMA: Preferred
Reporting Items for Systematic Reviews and Meta-Analyses)
(Moher et al., 2009). This required documenting the need
for a set of guidelines by reviewing previously published
systematic reviews and the methods and reporting of these,
reviewing existing literature to identify potential criteria. It
also draws on the methods used to establish CONSORT
(Consolidated Standards of Reporting Trials) (Moher, 1998) and
the Cochrane collaboration’s tool for assessing risk of bias in trials
(Higgins et al., 2011).
Therefore, at stage two, these criteria were put to a panel
(Delphi) of senior researchers, who were asked to rate their
FIGURE 1 | Flow diagram of stages and procedures in identification and evaluation of criteria for assessment of quality and/or human relevance in in vitro studies of
brain tumours.
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appropriateness for assessing quality and human relevance in
in vitro studies of brain tumours. Criteria reaching agreement
form the basis of the checklist reported in this study.
Summary of the Overall Approach
• Pre-stage (documenting the need for a set of
criteria/guidelines)
◦ Search for and review of previously published systematic
reviews in the field of in vitro cancer research.
◦ Examination of all papers described as systematic reviews
of in vitro cancer studies to assess the quality/relevance
assessment tools that had been used.
• Stage one (identifying potential criteria)
◦ Survey of senior brain tumour researchers to obtain a list
of all in vitro techniques that are used in brain tumour
research, suggested criteria, areas of agreement, relevant
guidance, or quality-related initiatives.
◦ Interviews with a pre-defined sample of leading
and emerging researchers, journal editors, senior
clinicians, funding body, and regulatory committee
representatives to elicit views on how quality and
relevance should be assessed.
◦ Examination of peer review guidelines from major
journals in the field for potential quality criteria for
in vitro studies.
◦ Identification and analysis of all documents presenting
potential quality criteria.
◦ Collation of the findings of the documentary analysis,
and the survey and interview data.
◦ Development of a draft set of criteria for assessing in vitro
studies based on the findings of the above.
• Stage two (gaining agreement on criteria for the guidelines)
◦ Establishment of a panel of experts in the field of brain
tumour in vitro research.
◦ Use of the Delphi method to obtain agreement on key
criteria to be used for assessing in vitro studies.
Pre-stage
Searches were carried out using five databases for systematic
reviews of in vitro cancer studies. All reviews that were described
as a ‘systematic review’ and which focused solely on in vitro
studies in any form of cancer were selected and the full-text
checked for relevance. Those that met the inclusion criteria were
selected and the data extracted on aspects including the focus and
methods used. The full details of this review are to be published
as a separate paper.
Stage One
Quality Criteria in Previously Published Systematic
Reviews
All relevant systematic reviews identified in the pre-stage review
were selected and the full-text checked for mention of, or
reference to, quality criteria, a checklist for quality, or guidance
used to judge quality and/or human relevance of included studies.
Survey of Brain Tumour Researchers
An online survey was conducted to investigate current areas
of research interest/focus related to in vitro research; in vitro
models and study methods used within these areas; methods for
assessing quality and relevance in these areas and knowledge of
any published guidelines, checklists or quality initiatives.
Questions were developed by the authors with a draft
version piloted followed by further revisions before the survey
was finalised. The survey was completed online, using the
University of Portsmouth’s online survey platform provider
(Online Surveys.ac.uk) and was completed anonymously. A copy
of the full set of questions in the questionnaire is available from
the authors on request.
Potential participants were identified from conference
abstracts for oral and poster presentations from international
conferences and scientific meetings. See Table 1 for a list of
sources used to identify potential participants. Once identified,
further information was sought on participants from publicly
available sources such as departmental, ResearchGate, and
Google Scholar web pages. Those meeting inclusion criteria and
for whom contact details could be found were approached for
participation. Inclusion criteria were:
• Scientist working on studies of brain tumours using
in vitro methods.
• Evidence of further publication history within brain tumour
field using in vitro methods beyond conference abstract
through which initially identified.
Potential participants were approached through published
email addresses obtained from conference abstracts,
departmental or professional web pages, or other publications.
Design of invitations was informed by Fan and Yan’s (2010)
recommendations drawn from a systematic review of factors
affecting response rates in web surveys. Email invitations
used a personalised salutation, identified survey tasks and
salience, described how recipients were identified as potential
participants, provided estimation of the time to finish the survey
and gave contact details for further questions and assistance
(Fan and Yan, 2010).
While no specific methodological guidance was available
for conducting surveys of pre-clinical scientists, this target
population was hypothesised to share many of the characteristics
likely to affect participation which have been identified in
previous studies with senior managers in other kinds of
organisation. These include increased sensitivity to personalised
responses, declining time capacity for participation due to
increasing pressures from their core roles (Cycyota and Harrison,
2006), and an increasingly saturated information environment
(e.g., email and social media) in which there are high levels
of competition for feedback (and thus participant time). The
potential vulnerability of the survey to low response in spite
of efforts to implement best practise guidance formed part of
the rationale for using multiple sources of data (i.e., survey,
interviews, and documentary analysis) to inform the Delphi
process, in order to make the project overall more resilient to the
limitations of any single data collection stream.
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TABLE 1 | Identification of potential participants by source.
Meeting/source Abstracts screened
(n)
Abstracts indicating
in vitro research (n)
Potential participants
excluded* (n)
Potential participants
approached (n)
World Federation of Neuro-oncology Societies
(WFNOS) 2017 Meeting (WFNOS, 2017a,b)
481 165 65 100
Society for Neuro-oncology (SNO) 2017 Annual
Meeting (SNO, 2017a,b)
1248 224 56 168
European Association of Neuro-Oncology 13th
Meeting (2018) (EANO, 2018)
446 157 61 96
British Neuro-Oncology Society (BNOS) 2017
Meeting (BNOS, 2018)
119 14 3 11
Asian Society for Neuro-Oncology (ASNO) 14th
Meeting (2017) (ASNO, 2017)
240 52 27 25
Sub-Saharan Africa Neuro-Oncology
Collaborative (S-SANOC) 2017 Planning
Meeting (S-SANOC, 2017)
25 17 14 3
Additional (potential participants identified
through other sources, e.g., team members or
other neuro-oncologists)
33
Totals 2559 629 193 436
*Not in vitro specialist OR not neuro-oncology specialist OR no contact information available.
Interviews With Key Individuals From the in vitro Field
Semi-structured interviews used widely to explore in-depth
contextual factors affecting practise change (e.g., regulatory,
funding, and variations in clinical or scientific practise) (Carlsen
et al., 2007; Gardner and Webster, 2016; Colquhoun et al.,
2017). A purposive sampling frame was constructed to reflect
the different roles relevant to in vitro research. These included
scientists, clinicians, regulators, and journal editors involved with
studies using in vitro methods (including those working in fields
other than brain tumour research, e.g., other neurological disease,
other forms of cancer). Participants were identified through
publications, professional and regulatory activities, and via the
project team. An interview guide was developed and piloted with
focus on the potential helpfulness and scope of set criteria, likely
extent of agreement on assessment of in vitro research and the
specific challenges in getting guidelines widely accepted.
The interviews aimed to explore:
• Professional opinion and practise in evaluation of quality
and human relevance of in vitro models for brain
tumour research, and identify points of agreement and
disagreement.
• Current practises, opinions, and resources for identifying
in vitro studies for review in brain tumour research.
• Factors that may promote or inhibit introduction of new
practises for assessment of quality and human relevance in
brain tumour research.
Interviews were carried out by phone after confirming
consent with the participant. All interviews were guided by
a set of core questions developed through pilot interviews,
with follow up questions and exploration taking place where
appropriate (and depending on the expertise and interest of
respective participants). The semi-structured nature of interviews
therefore meant that there was some variation in the length of
interviews, number of questions asked, and in development of
the interview schedule as the study progressed. Interviews were
recorded and transcribed for directed content analysis in Nvivo
(v12) Computer-assisted Qualitative Data Analysis Software
(CAQDAS) (QSR International, 2018). Nvivo allows users to
attach labels (or ‘codes’) to text, audio, video or image data,
and facilitates data management through which directed content
analysis can be conducted by a competent user. This involved
reading across interview transcripts to identify responses relevant
to the above aims (Corbin and Strauss, 2014).
Exploration of Author and Peer-Reviewer Guidance
Provided by Journals
A set of relevant journals was identified using the following
techniques:
• The 50 journals appearing most frequently in the results
of searching the Medline database using the index term
“In vitro Techniques+”.
• The 50 journals appearing most frequently using the
search “In vitro Techniques+” AND “Neoplasms+” (both
as index terms).
• The top 20 ranked journals from both the ‘Oncology’
and ‘Cancer Research’ categories of the Scimago Scientific
Journal Rankings.
Resulting journals were combined into a single list, which
after duplicate removal resulted in a set of unique journals
for assessment of author and peer-review guidance. Assessment
was conducted through manual exploration of journal websites,
to identify publicly available information on author and
peer-review guidance pertaining to quality assessment of
in vitro methods.
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Identification of Relevant Documents
Relevant documents including guidelines on the conduct and
reporting of in vitro research, published standards were identified
through the following methods:
• Previous review of published systematic reviews.
• 101 journal websites searched for general guidance on
in vitro-relevant study reporting, and quality appraisal for
specific techniques.
• Feedback from survey and interview responses.
• Searches of reporting guidance databases [e.g., US
National Institutes of Health (NIH), EQUATOR Network
FAIRSharing.org (2020)], the PubMed database and a
commercial social networking site for scientists and
researchers (ResearchGate).
All documents were loaded into NVivo software for directed
content analysis.
Analysis
Survey
Descriptive statistical analysis was performed on quantitative
data, and responses to free-text questions were analysed using
a content analysis approach, where data area grouped into
categories (e.g., cell line authentication and replication) for
reporting (Krippendorff, 2018). For this aspect of the SAToRI-
BTR project, data on quality and relevance criteria that are used
in practise (e.g., when peer reviewing) and any quality initiatives
or guidelines were extracted.
Interviews
Full interview transcripts were uploaded to Nvivo and directed
content analysis of data was performed using Nvivo. Through
this process, any data on quality and relevance criteria used in
practise, and any quality initiatives or guidelines were identified
and collated in order to inform stage two.
Documents
Directed content analysis was also performed on documents
using Nvivo software.
Collation and Compilation of List of Proposed Criteria
A full list of all criteria was generated and a comparison of the
criteria from documentary analysis compared with those from
the survey and interviews. Any additional criteria generated from
the latter were added to the list. The initial list was then further
reviewed for duplicate criteria (i.e., those assessing the same or
similar aspects but which were phrased in different terms which
could be merged), ensuring that those criteria highlighted in
several sources were retained and those that related only to a
specialised technique were removed. The outcome of stage one
was identification of a range of criteria for assessment of quality
and/or human relevance in in vitro studies of brain tumours,
which were organised in a taxonomy by area of focus.
Stage Two
Having identified potential assessment criteria for in vitro
studies of brain tumours at stage one through international
survey, telephone interview, and documentary analysis, stage
two involved evaluation of appropriateness of these criteria
for assessment of brain tumour studies by a panel of senior
scientists. The expert agreement panel (or ‘Delphi’) process has
been used extensively in clinical and health services research
to develop reporting guidance and quality assessment criteria
for a range of scientific and clinical applications (Fitch et al.,
2001; Boulkedid et al., 2011). Delphi allows participants to rate
criteria anonymously (i.e., without knowledge of the composition
of the panel, or identities of members), and to provide written
feedback on them. The process occurs across multiple rounds,
between which comments from all participants are also circulated
so each participant is aware of the range of opinions and
the reasons underlying these. Criteria reaching agreement are
removed, additional criteria may be added, or existing criteria
amended if they have not reached agreement (e.g., in response
to suggestions from the panel). The process is anonymous and
usually three rounds of the survey are sufficient to achieve
reasonable agreement (Fitch et al., 2001; Hsu Chia and Brian,
2007; Boulkedid et al., 2011).
Delphi has been used both as a standalone technique to reach
agreement on reporting and assessment criteria, and also as a
sorting procedure to identify criteria of ongoing controversy
requiring further discussion by a subsequent panel of experts
(Boulkedid et al., 2011). As the aim of SAToRI-BTR is to
identify agreed criteria, this method was assessed as appropriate
for either outcome in terms of wider development of the
project in the future.
Identification and Approach of Participants
Professors, heads of laboratories, and principal investigators
who had been previously identified at either the survey or
interview stages were invited to participate via personalised email
and physical letter as described at the survey stage. Following
indications of willingness to participate, participants were sent a
link to complete the online consent form, after which they were
invited to participate in the first round of the Delphi panel.
Development of Initial Criteria
Criteria identified at stage one were evaluated by expert members
of the SAToRI-BTR Team and results grouped into categories for
assessment by the panel.
Rating and Progression Between Rounds
Participants rated criteria on an 9-point scale: 1 (not at all
relevant) to 9 (essential) to assessment of a brain tumour study’.
They were invited to leave qualitative comments (e.g., on context
of application, clarity of criterion etc.) (Boulkedid et al., 2011) and
to suggest additional criteria for each category (see Figure 2).
Criteria were judged to have reached agreement according to
the RAND/UCLA agreement criteria (Fitch et al., 2001, p. 58).
Criteria reaching agreement were removed between rounds,
additional criteria added (if suggested by participants), and
existing criteria not reaching agreement changed in line with
participant feedback or (in its absence) passed to the next
round unchanged.
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FIGURE 2 | Example of Delphi rating scale and written feedback facility.
The final outcome of stage two was a set of criteria around
which agreement was obtained on their importance for the
assessment of quality and relevance.
Ethical Approval
Ethical approval for the survey, interviews, and Delphi processes
was granted by the University of Portsmouth Faculty of Science
Ethics Committee, reference number SFEC 2018-073 (original
application plus amendments).
RESULTS
Pre-stage (Review of Published
Systematic Reviews of in vitro Studies)
The review of published systematic reviews of in vitro studies
indicated that few were available. Not all those described
as systematic applied systematic approaches to the literature.
Analysis of the methods used in the reviews confirmed that there
was not a widely used set of criteria for assessing quality and/or
relevance of in vitro studies. Those that did conduct a systematic
appraisal of the included studies, adapted a wide range of existing
appraisal checklists. A lack of agreed criteria specific to in vitro
studies was highlighted.
Stage One
Survey of in vitro Brain Tumour Researchers
A total of 436 researchers were contacted and invited to
complete the online questionnaire (see Figure 3). Of those
invited, 7.8% (34 participants) completed the survey. Sixteen
were from the United States, 12 from Europe, five from the
United Kingdom and one from South America. A total of
10 different countries were represented. 30 (88%) participants
identified as either ‘Professor/Department Head’ or ‘Research
Team Lead.’ Mean years’ experience in brain tumour research
17.6 (SD = 10.1, range = 3–40). 28 participants (85%) also use
in vivo techniques. The participants recommended a range of
potential quality criteria.
Interviews
Thirty-four potential participants approached via email and
letter, of which 13 participants completed the interview
(see Figure 4). The participants included/represented:
professors/head of laboratories, consultant clinicians, industry,
those leading quality and human relevance initiatives, regulators
and journal editors. Telephone interviews totaled 414 min,
with an average length of 34.46 min (range = 17–58 min,
SD = 12.92 min).
Responses indicated:
• Methods for reviews of in vitro studies are highly variable;
• Quality of reviews of in vitro studies varies;
• Need for improved reporting standards.
Participants described a number of relevant quality assurance
documents and reporting standards. Views were also expressed
on the involvement of clinicians and regulators in development
and barriers to adoption of any suggested guidelines or quality
initiatives. More detailed results are to be reported in subsequent
published works.
Exploration of Author and Peer-Reviewer Guidance
Provided by Journals
Of the 101 unique journal titles identified, 6 journals had
been discontinued or renamed, 2 were book series and 1 journal
was inaccessible. Identifying and including the replacement titles
for the renamed journals resulted in a total of 96 journals
currently in print and accessible which could be assessed. Fifty-
eight (60%) journals did provide some guidance specific to or
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FIGURE 3 | Flow diagram of recruitment and results for international survey of brain tumour researchers.
FIGURE 4 | Flow diagram of recruitment and results for semi-structured interviews with stakeholders in in vitro studies of brain tumours.
relevant to in vitro techniques. Thirty-eight (40%) did not appear
to provide any guidance accessible on the website that was specific
to in vitro research. Established guidelines were reported by
25 journals (26%). These guidelines included those on specific
techniques which could be, but are not exclusively, applied
in in vitro research, such as MIAME (Minimum Information
About a Microarray Experiment) and STRENDA (Standards
for Reporting Enzymology Data). Generic guidelines were also
cited such as the National Institute for Health (NIH) Principles
and Guidelines for Reporting Preclinical Research. Cell line
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TABLE 2 | Quality assessment documents identified for analysis including sources.
Documents Survey Interviews Searches of
journal criteria
and assessment
databases
Tools for methodological quality and risk of bias (Al Saadi et al., 2016) Y
Cell culture techniques [edited collection] (Aschner et al., 2011) Y
Minimum information about a microarray experiment (MIAME)—toward standards for microarray data (Brazma
et al., 2001)
Y
STAR methods guide (CELL Press, 2020) Y Y
Six checklists relating to in vitro models for different organs/systems [COMMERCIAL ENTERPRISE]* Y
Quality of reporting in systematic reviews – meta-analyses of in vitro studies – a systematic review protocol (Elshafay
et al., 2019)
Y
Good cell culture practises and in vitro toxicology (Eskes et al., 2017) Y
EU-NETVAL meeting 10–11th October 2016 (EU-NETVAL, 2016) Y
EU-NETVAL meeting 26th–27th November 2015 (EU-NETVAL, 2015) Y
GOOD IN VITRO METHOD PRACTISES (GIVIMP) (OECD, 2018) Y
EURL ECVAM workshop – inaugural meeting of EU-NETVAL members – 26–27 June 2014 (EURL ECVAM, 2014) Y
Guidelines for the use of cell lines in biomedical research (Geraghty et al., 2014) Y
Perspectives on in vitro to in vivo extrapolations (Hartung, 2018) Y
Hartung et al. (2002) good cell culture practise ECVAM good cell culture practise task force report 1 (Hartung et al.,
2002)
Y
Definitions relating to cell line authentication (ICLAC, 2019b) Y Y Y
Cell line checklist for manuscripts and grant applications (ICLAC, 2019a) Y Y Y
Better reporting for better research: a checklist for reproducibility (Kenall et al., 2015) Y Y Y
UKCCCR guidelines for the use of cell lines in cancer research (UKCCCR, 2000) Y
Reporting recommendations for tumour marker prognostic studies (REMARK) (McShane et al., 2005; Altman et al.,
2012)
Y Y Y
Enhancing reproducibility through rigour and transparency (NOT-OD-15-103) (NIH-OER, 2015) Y Y
Guidelines for research involving recombinant or synthetic nucleic acid molecules (NIH, 2019) Y Y
Principles and guidelines for reporting preclinical research (NIH, 2017) Y Y
Advisory document of the working group on good laboratory practise the application of the principles of GLP to
in vitro studies (OECD, 2004)
Y
Good cell culture practise for stem cells and stem-cell-derived models (Pamies et al., 2017) Y
Extending a risk-of-bias approach to address in vitro studies – a systematic review protocol (Rooney, 2015) Y
In vitro acute and developmental neurotoxicity screening – an overview of cellular platforms and high-throughput
technical possibilities (Schmidt et al., 2017)
Y
Promoting coherent minimum reporting guidelines for biological and biomedical investigations – the MIBBI project
(Taylor et al., 2008)
Y
*Documents marked [COMMERCIAL ENTERPRISE] were provided on condition of confidentiality of content.
authentication was referred to by 22 journals and related
guidance that was cited included the UKCCCR Guidelines for
the Use of Cell Lines in Cancer Research. A full list of the
guidance that was located through review of the journal websites
is included in Table 2.
For all journals still in publication and with an impact factor
for 2018 (n = 95), the median impact factor (IF) was 4.9
(range = 0.6–223.7, IQR = 5.6). Of these: for journals citing
established criteria (n = 25) the median was 5.2 (range = 1.9–
59.1, IQR = 3.5); for journals giving general guidance (n = 48)
the median was 4.9 (range = 1.9–41.1, IQR = 3.5); while for
journals giving no specific guidance (n = 37) the median was 4.5
(range = 0.6–223.7, IQR = 6.7).
The analysis of author and peer-review guidance provided
further evidence to support the observation of a lack of common,
comprehensive, quality assessment criteria for in vitro studies,
by showing significant variation in the quantity and types of
guidance provided by journals.
Documentary Analysis
A total of 32 documents were identified from the above sources
(see Table 2). Criteria identified from analysis of these documents
are reported below as part of the summary of all criteria identified
from stage one (see Figure 5).
Stage Two
Compilation of Preliminary Criteria
Following completion of the survey, interview, and documentary
analysis stages, potential criteria were collated using Nvivo
software, through which a long list of 129 preliminary items
were identified (see Figure 6). Duplicate and highly context
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FIGURE 5 | Flow diagram describing sources of identification of reporting guidance documents, and initial criteria for reporting of in vitro studies of brain tumours
resulting from documentary analysis.
specific items were removed. Forty-one criteria were selected for
assessment by expert panel (Delphi) (see Table 3).
Expert Panel
Of the 38 professors, heads of laboratories, and principal
investigators invited to participate by personalised email and
letter, 22 agreed to participate initially. 19 participants completed
round one and 18 completed round two (see Figure 6). For a
comparison of those participating in the expert panel compared
with those taking part in the survey and interviews, see Table 4.
Delphi Assessment
Of the initial 41 criteria, agreement was achieved in round
one on 28 with no agreement on 13. Seven further criteria
were suggested.
For round two, based on feedback from participants, four of
the 13 criteria were merged with existing criteria, nine were re-
presented to Delphi group (with or without rephrasing) and the
seven new criteria identified by participants were also presented
to the panel. Thus, a total of 16 criteria were assessed in round
two and a total of 48 criteria across the two rounds.
In round two agreement was achieved on nine (including
three new criteria). No agreement was apparent on seven
criteria (including four new criteria). Although the level of
agreement across the two rounds of Delphi completed was high,
for the remaining seven criteria, the level of agreement, even
when criteria were rephrased reduced and the feedback from
participants indicated that achieving agreement on these was
unlikely to be feasible.
The large amount of qualitative data to analyse (comments,
explanations etc.) collected should further inform the application
of the criteria in practise. Further specification of criteria needs
discussion and, thus, it was decided that the next stage would
require an in-person meeting and discussion. A summary of the
process is shown in Table 4, and in Figure 6.
DISCUSSION
This study represents a first attempt to use a systematic approach
to generating a set of criteria for assessing the quality and
relevance of in vitro brain tumour research studies. In designing
the process, the aim was to combine a systematic analysis of
existing guidance and practise with the implicit views of those
with expertise in in vitro brain tumour research. By attempting to
engage those involved in research in this field at an early stage and
throughout the process, it was anticipated that the uptake of any
resulting guidance would be optimised. It was also anticipated
that focusing the study in a specific area (brain tumour research)
would also increase the relevance and hence engagement with
the process.
There have been a number of initiatives aimed at improving
and standardising the quality and reporting of in vitro research,
some of which are ongoing (Eskes et al., 2017; Pamies et al.,
2017; OECD, 2018; Hartung et al., 2019). Full and transparent
reporting is of importance as it enables the evaluation and
reproduction by other researchers and thus optimises the
resources that have been expended. While various initiatives
have been undertaken, adoption by researchers working in
the field has been low (Pamies et al., 2017). The participants
taking part in the survey and interviews conducted in this
study were aware of some of these initiatives but there
was not universal or consistent reference to any particular
set of guidance.
The intention of screening a large number of abstracts from
a series of relevant recent conferences was to ensure that a
large number of researchers were involved in the survey (and
thus the guideline production process). Over 2,500 abstracts
were screened resulting in over 400 individual senior researchers
being identified but the response rate was extremely low.
There may be several explanations for this: lack of perceived
relevance or concern about the ultimate aim of any guidance
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FIGURE 6 | Flow diagram describing Delphi process and outcomes.
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TABLE 3 | Summary of Delphi process (italics: no agreement).
Category Criteria Delphi round 1 Agreement
(n = 19)
Median Criteria Delphi
round 2
Agreement
(n = 18)
Median Criteria reaching
agreement
General Ethical approval N 5 Changed to:
Ethical approval
for cells from
human donors
N 8 –
Compliance with Good
Laboratory Practise (GLP)
Y+ 9 – Compliance with Good
Laboratory Practise (GLP)
Initial
set-up and
processes
Transportation conditions for
tissues/cells
Y+ 9 – Transportation conditions for
tissues/cells
Quarantine process for new
cells
N 8 Changed to:
Quarantine
process in
place for cells
introduced from
other
laboratories
Y+ 9 Quarantine process in place
for cells introduced from
other laboratories
Testing for micro-organisms Y+ 9 – Testing for micro-organisms
Cell authentication Y+ 9 – Cell authentication
Method of primary culture
establishment
Y+ 9 – Method of primary culture
establishment
Cell detachment and
disaggregation methods
N 7 Unchanged Y+ 7 Cell detachment and
disaggregation methods
Take rate of primary culture
establishment
N 6.5 Changed to:
Success rate
for establishing
primary culture
N 8 –
Sources of reagents Y+ 9 – Sources of reagents
Consistent use of reagents Y+ 9 – Consistent use of reagents
Cells Origin or source of cells
(whether tissue, biopsy-derived
early passage or cell lines)
Y+ 9 – Origin or source of cells
(whether tissue,
biopsy-derived early passage
or cell lines)
Cell authenticity Y+ 9 – Cell authenticity
Genomic stability N 7 Changed to:
Researcher
awareness of
genomic
instability
Y+ 9 Researcher awareness of
genomic instability
Passage number (reduced
heterogeneity and acquired
resistance)
Y+ 9 Passage number (reduced
heterogeneity and acquired
resistance)
Cell characterisation
(morphology, differentiation and
antigenicity)
Y+ 9 Cell characterisation
(morphology, differentiation
and antigenicity)
Population doubling times N 8 Unchanged Y+ 7 Population doubling times
Cell viability testing Y+ 8 – Cell viability testing
Cryopreservation
process/method
Y+ 9 – Cryopreservation
process/method
Models Patient-derived (human) Y+ 9 – Patient-derived (human)
Cellular heterogeneity Y+ 8 – Cellular heterogeneity
Culture conditions 1 (HEPES or
CO2 incubation)
Y+ 9 – Culture conditions 1 (HEPES
or CO2 incubation)
Culture conditions 2
(temperature, oxygen, pH, and
humidity)
Y+ 9 – Culture conditions 2
(temperature, oxygen, pH,
and humidity)
Serum supplementation
(human, FCS/NCS or
serum-free)
Y+ 9 – Serum supplementation
(human, FCS/NCS, or
serum-free)
(Continued)
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TABLE 3 | Continued
Category Criteria Delphi round 1 Agreement
(n = 19)
Median Criteria Delphi
round 2
Agreement
(n = 18)
Median Criteria reaching
agreement
Complexity of the model (3D
versus 2D)
Y+ 9 – Complexity of the model (3D
versus 2D)
Vascular flow N 5 Merged * – –
Use of antimycotics and/or
antibiotics
N 7 Changed to: If
used, effect of
antimycotics
and/or
antibiotics on
cell growth
Y+ 7 If used, effect of antimycotics
and/or antibiotics on cell
growth
Tumour microenvironment (e.g.,
immune cells and
non-neoplastic glial cells)
N 8 Unchanged N 9 –
Representation in the model of
the physiology of intended
patients
N 7 Merged * – –
Assays Multimodality assays N 7 Changed to:
Validation of
results using
multiple
methods
Y+ 7.5 Validation of results using
multiple methods
Functional assays (biological
behaviour)
Y+ 8 – Functional assays (biological
behaviour)
Replicated assays Y+ 9 – Replicated assays
Appropriate controls Y+ 9 – Appropriate controls
Therapeutic testing N 7 Merged ** – –
Blood brain barrier N 6 Merged * – –
Interpretation
by authors
Reproducibility of results
(within-laboratory)
Y+ 9 – Reproducibility of results
(within-laboratory)
Reproducibility of results
(between laboratory
transferability)
Y+ 8 – Reproducibility of results
(between laboratory
transferability)
Definition of the human
relevance of the in vitro model
Y+ 8 – Definition of the human
relevance of the in vitro model
Demonstration of the
relationship of the model to the
target tissue or organ
Y+ 9 – Demonstration of the
relationship of the model to
the target tissue or organ
Discussion of the limitations of
the method
Y+ 9 – Discussion of the limitations
of the method
Discussion of the limitations of
the model
Y+ 9 – Discussion of the limitations
of the model
Additional
criteria
proposed
by Delphi
panel
members
– – Reporting of
Standard
Operating
Procedures
(SOPs) to aid
replication
Y+ 9 Reporting of Standard
Operating Procedures (SOPs)
to aid replication
– – Pathology/patient
data reported
or accessible
Y+ 9 Pathology/patient data
reported or accessible
– – Sampling of
different
regions of
heterogeneous
tumour
N 7 –
– – Time interval
between
collecting
biopsy tissue
and setting up
primary culture
N 9 –
(Continued)
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TABLE 3 | Continued
Category Criteria Delphi round 1 Agreement
(n = 19)
Median Criteria Delphi
round 2
Agreement
(n = 18)
Median Criteria reaching
agreement
– – Substrate on
which cells are
cultured
Y+ 8.5 Substrate on which cells are
cultured
– – Assessment of
imaging
method used
N 7 –
– – Appropriate
use of
bioinformatics
and/or
mathematical
modelling
N 7 –
* Criterium merged with Demonstration of the relationship of the model to the target tissue or organ (Criteria Delphi round 1). ** Criterium merged with Multimodality
assays (Criteria Delphi round 1).
TABLE 4 | Comparison of participants in survey, interviews and Delphi.
Country Surveys Interviews Delphi Minimum number of individuals participating in at least one stage
Brain tumour in vitro researchers All participants
Belgium 1 1 1 1
Brazil 1 1 1
Germany 4 1 2 4 5
Ireland 1 2 2 2
Italy 1 1 1 1
Luxembourg 1 1 1
Netherlands 3 3 3
Norway 1 2 2 2
Poland 1 1 1
Slovenia 1 1 1
Sweden 1 1 1
United Kingdom 5 11 7 7 15
United States 16 2 16 16
Total 34 13 19 41 50
may have discouraged participation. Other practical problems
such as contact emails being filtered out by organisational email
servers may also have had an impact. Additionally, the field
of brain tumour research has, historically, been poorly funded
(House of Commons Petitions Committee [HCPC], 2016) so
that researchers are likely to be focused on core issues including
grant income and job security and we anticipated that they may
be less inclined to become involved in research that appears
more peripheral to these aspects. Because of this, we chose
a study design (as summarised in Figure 1) which drew on
multiple data collection streams to inform the criteria for Delphi
assessment (survey, interview, and documentary analysis). This
was to ensure that the study design was resistant to risks
associated with low response rates to survey or interviews.
Nevertheless, more than 30 heads of laboratories/professors from
10 different countries did participate and, overall 40 in vitro
brain tumour experts from 13 countries contributed to at least
one stage of the process. This is a significant number in a
relatively small field and these people represent experienced,
senior authorities within the field. Furthermore, there was
consistency in the criteria suggested in the survey, interview,
and documents.
There was also consistency and a high level of agreement
on the importance of each of the criteria proposed. The final
outcome of the process reported in this paper is a set of 37 criteria
which reached agreement as essential to consider when assessing
the quality and/or human relevance of an in vitro study. The
focus was on in vitro research in the brain tumour field but the
majority of the criteria generated are generic and could be applied
to other in vitro research areas, particularly those in the field
of cancer.
The data collected included individual comments and
feedback on each of the criteria and revealed areas where
there are differences in opinions and practise which would
benefit from further investigation. It will be necessary to further
specify how each of the ‘criteria’ could best be applied in
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practise as, in some cases, this is implicit and/or context-
specific rather than explicit and/or universal. Thus, criteria
refer to specific aspects of an in vitro study that should be
assessed and not whether simply reporting this would constitute
good practise or whether it is also necessary that the study
meets a particular standard related to this aspect. For example,
there was agreement on the importance of assessing ‘cellular
heterogeneity’ but no specific standard of reporting or conduct
is currently attached to this. The data collected will inform the
next stage of the process which is to develop more detailed
guidance on the application of the criteria in practise. This
may require an in person meeting as is generally required
for finalising guidance such as this (EQUATOR Network,
2020). Ultimately, the set of guidance generated could be
disseminated and used by journals, grant awarding bodies,
and peer reviewers. As has been proposed, producing and
disseminating a set of agreed criteria for the assessment of in vitro
studies will further support ‘Meaningful contributions to the
body of science’ as they can evaluated and reproduced by other
researchers in the field and are more accessible to those in
related fields previously (Hartung et al., 2019).
CONCLUSION
The SAToRI-BTR project drew on a range of well-established
methods for identification and appraisal of current practise
standards. Through a rigorous, systematic process of expert
review, the project has resulted in a set of preliminary criteria
for use in assessment of quality and human relevance of in vitro
brain tumour studies. Further development of these criteria,
including potential strategies for adaptation and dissemination
across different sub-fields of brain tumour research, will follow.
While the focus of the study remains in the brain tumour
field, the initial criteria identified and the methods through
which they were developed remain applicable to a broader
range of fields relating to in vitro research. It is therefore
hoped that this investigation will prove useful empirically and
methodologically, both within and beyond the specific focus of
brain tumour studies.
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